Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Enzyme Inhibitors as the Attractive Targets for the Treatment of Various Diseases.

Current medicinal chemistry

Orhan IE.
PMID: 31526340
Curr Med Chem. 2019;26(18):3206-3207. doi: 10.2174/092986732618190821115641.

No abstract available.

Cite
Orhan IE. Enzyme Inhibitors as the Attractive Targets for the Treatment of Various Diseases. Curr Med Chem. 2019;26(18):3206-3207doi: 10.2174/092986732618190821115641.
Orhan, I. E. (2019). Enzyme Inhibitors as the Attractive Targets for the Treatment of Various Diseases. Current medicinal chemistry, 26(18), 3206-3207. https://doi.org/10.2174/092986732618190821115641
Orhan, Ilkay Erdogan. "Enzyme Inhibitors as the Attractive Targets for the Treatment of Various Diseases." Current medicinal chemistry vol. 26,18 (2019): 3206-3207. doi: https://doi.org/10.2174/092986732618190821115641
Orhan IE. Enzyme Inhibitors as the Attractive Targets for the Treatment of Various Diseases. Curr Med Chem. 2019;26(18):3206-3207. doi: 10.2174/092986732618190821115641. PMID: 31526340.
Copy Download .nbib Format: NLM
In silico identification of potential inhibitors against human 2'-5'- oligoadenylate synthetase (OAS) proteins.

Computational biology and chemistry

Gonzalez KJ, Moncada-Giraldo DM, Gutierrez JB.
PMID: 32004971
Comput Biol Chem. 2020 Apr;85:107211. doi: 10.1016/j.compbiolchem.2020.107211. Epub 2020 Jan 22.

As part of the type I IFN signaling, the 2'-5'- oligoadenylate synthetase (OAS) proteins have been involved in the progression of several non-viral diseases. Notably, OAS has been correlated with immune-modulatory functions that promote chronic inflammatory conditions, autoimmune disorders,...

Cite
Gonzalez KJ, Moncada-Giraldo DM, Gutierrez JB. In silico identification of potential inhibitors against human 2'-5'- oligoadenylate synthetase (OAS) proteins. Comput Biol Chem. 2020;85:107211doi: 10.1016/j.compbiolchem.2020.107211.
Gonzalez, K. J., Moncada-Giraldo, D. M., & Gutierrez, J. B. (2020). In silico identification of potential inhibitors against human 2'-5'- oligoadenylate synthetase (OAS) proteins. Computational biology and chemistry, 85107211. https://doi.org/10.1016/j.compbiolchem.2020.107211
Gonzalez, Karen J, et al. "In silico identification of potential inhibitors against human 2'-5'- oligoadenylate synthetase (OAS) proteins." Computational biology and chemistry vol. 85 (2020): 107211. doi: https://doi.org/10.1016/j.compbiolchem.2020.107211
Gonzalez KJ, Moncada-Giraldo DM, Gutierrez JB. In silico identification of potential inhibitors against human 2'-5'- oligoadenylate synthetase (OAS) proteins. Comput Biol Chem. 2020 Apr;85:107211. doi: 10.1016/j.compbiolchem.2020.107211. Epub 2020 Jan 22. PMID: 32004971.
Copy Download .nbib Format: NLM
Serendipity in discovery of proteasome inhibitors.

Bioorganic & medicinal chemistry letters

Dunn D, Iqbal M, Husten J, Ator MA, Chatterjee S.
PMID: 22503349
Bioorg Med Chem Lett. 2012 May 15;22(10):3503-5. doi: 10.1016/j.bmcl.2012.03.086. Epub 2012 Mar 29.

Among its various catalytic activities, the 'chymotrypsin-like' activity of the proteasome, a large multicatalytic proteinase complex has emerged as the focus of drug discovery efforts in cancer therapy. Herein, a series of first generation (2S, 3R)-2-amino-3-hydroxybutyric acid derived proteasome...

Cite
Dunn D, Iqbal M, Husten J, et al. Serendipity in discovery of proteasome inhibitors. Bioorg Med Chem Lett. 2012;22(10):3503-5doi: 10.1016/j.bmcl.2012.03.086.
Dunn, D., Iqbal, M., Husten, J., Ator, M. A., & Chatterjee, S. (2012). Serendipity in discovery of proteasome inhibitors. Bioorganic & medicinal chemistry letters, 22(10), 3503-5. https://doi.org/10.1016/j.bmcl.2012.03.086
Dunn, Derek, et al. "Serendipity in discovery of proteasome inhibitors." Bioorganic & medicinal chemistry letters vol. 22,10 (2012): 3503-5. doi: https://doi.org/10.1016/j.bmcl.2012.03.086
Dunn D, Iqbal M, Husten J, Ator MA, Chatterjee S. Serendipity in discovery of proteasome inhibitors. Bioorg Med Chem Lett. 2012 May 15;22(10):3503-5. doi: 10.1016/j.bmcl.2012.03.086. Epub 2012 Mar 29. PMID: 22503349.
Copy Download .nbib Format: NLM
Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes.

Mini reviews in medicinal chemistry

Hale C, Wang M.
PMID: 18537725
Mini Rev Med Chem. 2008 Jun;8(7):702-10. doi: 10.2174/138955708784567421.

Glucocorticoid action is linked to the development of obesity and insulin resistance. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) has been proposed as a strategy to suppress glucocorticoid action in a tissue-specific manner. A large variety of 11beta-HSD1 inhibitor...

Cite
Hale C, Wang M. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem. 2008;8(7):702-10doi: 10.2174/138955708784567421.
Hale, C., & Wang, M. (2008). Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini reviews in medicinal chemistry, 8(7), 702-10. https://doi.org/10.2174/138955708784567421
Hale, Clarence, and Wang, Minghan. "Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes." Mini reviews in medicinal chemistry vol. 8,7 (2008): 702-10. doi: https://doi.org/10.2174/138955708784567421
Hale C, Wang M. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem. 2008 Jun;8(7):702-10. doi: 10.2174/138955708784567421. PMID: 18537725.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries